Genmab — Februar 2017
-
Så hvis JNJ byder 2 milliarder EUR, så byder MorphoSys aktionærer nok på. Udover dette har de I forvejen samarbede om Guselkumab, som er MorphoSys mest værdifulle product
-
bider nok på
-
ahhhh mr doom er vågnet. Godmorgen!
-
haha
-
Dejligt at du er tilbage OHW.

-
MorphoSys stiger 0,8%. Så ikke noget markedet tager alvorligt
-
Lad os bare få nogle flere meddelelser fremover om patentsagen til at kickstarte vores morgen i positivt terræn.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind